<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BU and CY is a common conditioning regimen for allogeneic hematopoietic progenitor cell transplantation (HPCT) </plain></SENT>
<SENT sid="1" pm="."><plain>I.v </plain></SENT>
<SENT sid="2" pm="."><plain>BU is increasingly used in place of the oral formulation for conditioning </plain></SENT>
<SENT sid="3" pm="."><plain>We compared the outcomes of 135 consecutively treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients who underwent allogeneic HPCT at our institution with BUCY2 using oral (n=93) or i.v </plain></SENT>
<SENT sid="4" pm="."><plain>(n=42) BU, without dose adjustment </plain></SENT>
<SENT sid="5" pm="."><plain>The i.v </plain></SENT>
<SENT sid="6" pm="."><plain>BU patients had a lower incidence of any severity of <z:e sem="disease" ids="C1568868" disease_type="Disease or Syndrome" abbrv="">oral mucositis</z:e> (3 versus 55%, P=0.002) and severe mucositis (3 versus 24%, P=0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>Other post transplant outcomes were comparable between the groups </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> 26 i.v </plain></SENT>
<SENT sid="9" pm="."><plain>BU and 33 oral BU patients are alive; however, the median follow-up was significantly longer for the oral BU group </plain></SENT>
<SENT sid="10" pm="."><plain>One- and two-year non-relapse mortality for the i.v </plain></SENT>
<SENT sid="11" pm="."><plain>BU patients was 21% for both, and for the oral BU group was 23% and 29%, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>One- and two-year relapse mortality for the i.v </plain></SENT>
<SENT sid="13" pm="."><plain>BU patients was 21% for both, and for the oral BU group was 24% and 29%, respectively </plain></SENT>
<SENT sid="14" pm="."><plain>Substituting i.v. for oral BU reduces variability in drug exposure and potentially improves toxicity as suggested by our finding of significantly less <z:e sem="disease" ids="C1568868" disease_type="Disease or Syndrome" abbrv="">oral mucositis</z:e> and decreased severity with i.v </plain></SENT>
<SENT sid="15" pm="."><plain>BU </plain></SENT>
</text></document>